Alyssa Lange

Ms. Alyssa Lange

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ALAlyssa Lange
Alyssa Lange
SMSriGita Madiraju
SriGita Madiraju
FPFiras G. Petros
Firas G. Petros
Purpose: Bacillus Calmette–Guérin (BCG) has long been the standard treatment for preventing recurrence and progression following resection of high-risk non-muscle invasive bladder cancer (NMIBC). Unfortunately, recurrence or progression despite BCG induction and maintenance treatment have significant prevalence—a persistent issue in urologic oncology. Notable advancements in the development of alternative therapeutic options have become available and are in the pipeline. This review aims to provide an overview of the current treatment landscape for patients with BCG-unresponsive NMIBC, highlighting both existing and emerging therapies that are expected to become more widely available. Methods: A narrative review based on data collected through the end of 2024. Results: Several treatment options, aside from radical cystectomy (RC), are currently available or in promising stages of clinical trials. Many of these treatment modalities were granted Fast Track and Breakthrough Therapy status due to their initial success. These include novel chemotherapy regimens, immune checkpoint inhibitors, device-assisted therapies, and new intravesical and systemic agents. Combination therapies combining traditional treatments and newer approaches were explored. Conclusions: The next few years promise to offer patients a variety of new, effective therapies for BCG-unresponsive NMIBC. These advancements hold significant potential for improving patient outcomes and providing more targeted, organ-sparing treatment options.

30 January 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
SMShahdi Kendra Malakooti
Shahdi Kendra Malakooti
HSHinnah Siddiqui
Hinnah Siddiqui
BWBrigid Wilson
Brigid Wilson
TBTaissa Bej
Taissa Bej
MOMegan O’mara
Megan O’mara
DADonald Anthony
Donald Anthony
(1) Vitamin D deficiency is associated with mortality in the general population and has been observed in one rheumatoid arthritis (RA) cohort. Here, we investigate the relationship between 25-hydroxyvitamin D (25(OH)D) levels before methotrexate (MTX) therapy initiation in patients with RA and the subsequent all-cause mortality in a national Veterans Affairs (VA) cohort. (2) This is a retrospective study on RA patients time-oriented around the initial MTX prescription and 25(OH)D levels before starting MTX. We examined survival in patients with 25(OH)D levels > 50 nmol/L and ≤50 nmol/L using the Cox Proportional Hazard Model and fully adjusted for risk factors. (3) In total, 15,109 RA patients were included in the nationwide cohort. RA patients with 25(OH)D levels > 50 nmol/L before starting MTX had a 28% reduced risk of mortality when compared to those with levels ≤ 50 nmol/L (HR: 0.72, CI: 0.64–0.80, p < 0.001) after adjusting for traditional risk factors. (4) In this national RA cohort receiving standard-of-care MTX, patients with 25(OH)D levels > 50 nmol/L have a lower subsequent mortality when compared to those with 25(OH)D levels ≤ 50 nmol/L. It remains to be determined whether increasing Vitamin D levels in RA patients initially found to be Vitamin D deficient impacts their all-cause mortality.

1 January 2025 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
ALAlyssa Lange
Alyssa Lange
NDNicole Dominiak
Nicole Dominiak
FPFiras G. Petros
Firas G. Petros
Background: Inflammatory myofibroblastic tumors (IMT) are uncommon with an estimated 150– 200 people being diagnosed in the US annually. We describe a healthy adult male who presented with an enlarging, painless scrotal mass. Based on current literature, only nine epididymal inflammatory myofibroblastic tumors have been reported and in this case report we describe the tenth. Case Presentation: A 40-year-old Caucasian male presented with an enlarging mass near his right testicle with no associative symptoms or obvious etiology. Scrotal ultrasound showed a solid heterogenous mass with internal vascularity. Tumor markers were unremarkable for lactate dehydrogenase (LDH), beta-human chorionic gonadotropin (b-hCG), and alpha-fetoprotein (AFP). A right inguinal approach was performed. A 2– 3 cm round mass adjacent to the tail of the epididymis was excised with clear margins and sent to pathology. Histology confirmed a 2.4 cm inflammatory myofibroblastic tumors with scattered positivity for smooth muscle actin, negative pancytokeratin, and negative anaplastic lymphoma kinase. Patient recovered well with no reoccurrence at this time. Conclusion: Inflammatory myofibroblastic tumors recurrence rate is < 2%; however, some literature suggests higher depending on location and immunohistochemical profile. The expertise of pathologists, utilization of morphology, and immunohistological profile are all crucial in accurate diagnoses of these lesions. Literature reports some lesions have demonstrated metastatic tendencies and therefore complete excision of the mass is the recommended therapy of choice. This case highlights the increasing need to include IMT in differential diagnoses for patients presenting with painless lumps even in unlikely locations. While there is little data on epididymal tail mass recurrence rate potential, we report no current recurrence after complete excision of the mass.

Verified
Journal Article
Open access
PDF file
HPHerleen Pabla
Herleen Pabla
ALAlyssa Lange
Alyssa Lange
Nagalakshmi NadimintyNagalakshmi Nadiminty
Nagalakshmi Nadiminty
Puneet SindhwaniPuneet Sindhwani
Puneet Sindhwani
Background/Objectives: Using chatbots to seek healthcare information is becoming more popular. Misinformation and gaps in knowledge exist regarding the risk and benefits of testosterone replacement therapy (TRT). We aimed to assess and compare the quality and readability of responses generated by four AI chatbots. Methods: ChatGPT, Google Bard, Bing Chat, and Perplexity AI were asked the same eleven questions regarding TRT. The responses were evaluated by four reviewers using DISCERN and Patient Education Materials Assessment Tool (PEMAT) questionnaires. Readability was assessed using the Readability Scoring system v2.0. to calculate the Flesch–Kincaid Reading Ease Score (FRES) and the Flesch–Kincaid Grade Level (FKGL). Kruskal–Wallis statistics were completed using GraphPad Prism V10.1.0. Results: Google Bard received the highest DISCERN (56.5) and PEMAT (96% understandability and 74% actionability), demonstrating the highest quality. The readability scores ranged from eleventh-grade level to college level, with Perplexity outperforming the other chatbots. Significant differences were found in understandability between Bing and Google Bard, DISCERN scores between Bing and Google Bard, FRES between ChatGPT and Perplexity, and FKGL scoring between ChatGPT and Perplexity AI. Conclusions: ChatGPT and Google Bard were the top performers based on their quality, understandability, and actionability. Despite Perplexity scoring higher in readability, the generated text still maintained an eleventh-grade complexity. Perplexity stood out for its extensive use of citations; however, it offered repetitive answers despite the diversity of questions posed to it. Google Bard demonstrated a high level of detail in its answers, offering additional value through visual aids. With improvements in technology, these AI chatbots may improve. Until then, patients and providers should be aware of the strengths and shortcomings of each.

5 November 2023 in Cureus
Verified
Journal Article
Open access
PDF file
JMJosh W Vander Maten
Josh W Vander Maten
CSChristopher G Sanford
Christopher G Sanford
MMMatthew McCracken
Matthew McCracken
ESElisabeth Sohn
Elisabeth Sohn
ALAlyssa Lange
Alyssa Lange
JLJiayong Liu
Jiayong Liu
Background Screw fixation continues to be a commonly used treatment for syndesmotic disruption; however, screw breakage remains a complication post-fixation. Despite this complication, investigation on the variability of surgical placement in conjunction with syndesmotic screw characteristics affecting breakage has not been fully elucidated. The purpose of this study is to compare patients with syndesmotic screw breakage versus those with intact screws based on surgically controlled variables. Methods A total of 176 patients and 260 syndesmotic screws were included in the study, 88 patients each with and without broken syndesmotic screws. A retrospective analysis of patients who underwent syndesmotic screw fixation was performed. Patients with syndesmotic screw breakage were compared to those with intact screws. Screw width and length, the number of screws used, fracture type, and the number of cortices for fixation were all collected. Further analysis included radiographic measurement of syndesmotic screw angle and height of placement above the tibial plafond. Results Decreased screw width, increased number of screws used, and younger age were all associated with increased rates of screw breakage (p < .001, p = .019, p = 0.020). No statistical difference was appreciated between groups based on screw length, number of cortices used, or angle relative to the tibial plafond (p = .2432, p = .4699, p = .9233). Conclusion Higher placement of syndesmotic screws above the tibiotalar joint, specifically greater than 20 mm above the tibial plafond, increases the screw breakage rate. Decreased screw width, increasing numbers of screws used, and younger age were all also associated with increased rates of screw breakage. No difference was appreciated based on the screw angle relative to the tibial plafond.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
SDSofi Damjanovska
Sofi Damjanovska
DKDaniel Karb
Daniel Karb
ACAllen Chen
Allen Chen
ALAlyssa Lange
Alyssa Lange
GIGerard A. Isenberg
Gerard A. Isenberg